DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2021-0009]

Grant of Interim Extension of the Term of U.S. Patent No. 7,534,790; Vernakalant Hydrochloride


ACTION: Notice of interim patent term extension.


FOR FURTHER INFORMATION CONTACT: Raul Tamayo by telephone at 571-272-7728; by mail marked to his attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313-1450; by fax marked to his attention at 571-273-7728; or by email to raul.tamayo@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent.

On February 9, 2021, Correvio International Sàrl, the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for a third interim extension of the term of U.S. Patent No. 7,534,790. The patent claims the human drug product vernakalant hydrochloride. The application for patent term extension indicates that New Drug Application (NDA) 22-034 was submitted to the Food and Drug Administration (FDA) on December 19, 2006.
Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory review period will continue beyond the twice-extended expiration date of the patent, March 31, 2021, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,534,790 is granted for a period of one year from the extended expiration date of the patent.

Robert Bahr,

Deputy Commissioner for Patent Examination Policy,


[FR Doc. 2021-03427 Filed: 2/18/2021 8:45 am; Publication Date: 2/19/2021]